Feasibility and patient reported tolerance of cryotherapy with Cooral mouth cooling device in patients undergoing radiation therapy (CooRay): a pilot study.
{"title":"Feasibility and patient reported tolerance of cryotherapy with Cooral mouth cooling device in patients undergoing radiation therapy (CooRay): a pilot study.","authors":"Andrei Bunea, Tiberiu Damian, Hatice Bunea, Tobias Finazzi, Tristan Bauer, Jens Lustenberger, Shirin Davarpanah Jazi, Alexandros Papachristofilou","doi":"10.21037/tcr-24-1313","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radiation-induced oral mucositis (RIOM) is a major side-effect of (chemo)radiation (CRT) of patients with head and neck cancer (HNC). This study tries to establish a novel cryotherapy (CyT) method using a mouth care device (MCD; Cooral<sup>®</sup>, BrainCool AB, Lund, Sweden) to prevent RIOM.</p><p><strong>Methods: </strong>Patients were non-randomly assigned to use the MCD after every radiotherapy session for 30-60 minutes. Subjects were asked to answer daily questionnaires assessing tolerability of the intervention. Mucositis was assessed at baseline, once weekly and at weeks 1/3/6 after CRT. The primary endpoint was patient tolerance, defined by the time the MCD was used and the patients' perception. Secondary outcomes were the degree (CTCAE v5.0) and duration of RIOM.</p><p><strong>Results: </strong>Ten patients were eligible with a mean age of 62 years. Four patients received concurrent platinum-based CRT, whereas the others received radiotherapy alone. Overall, 214 CyT sessions were performed (73% of planned CyT sessions). The mean daily CyT duration was 48 minutes (range, 30-60 minutes). All patients reported cooling as comfortable. Nine completed the intervention, one terminated it early due to hypersalivation. No Grade 4 RIOM was observed. Grade 3 mucositis was observed in 4 and Grade 2 in 3 cases.</p><p><strong>Conclusions: </strong>The Cooral System was well tolerated, with a duration of application that was acceptable for most patients. We concluded that the MCD can be safely used in patients undergoing CRT. A prospective phase II trial, assessing the efficacy in preventing RIOM, is planned.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 3","pages":"1874-1883"},"PeriodicalIF":1.5000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11985184/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1313","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Radiation-induced oral mucositis (RIOM) is a major side-effect of (chemo)radiation (CRT) of patients with head and neck cancer (HNC). This study tries to establish a novel cryotherapy (CyT) method using a mouth care device (MCD; Cooral®, BrainCool AB, Lund, Sweden) to prevent RIOM.
Methods: Patients were non-randomly assigned to use the MCD after every radiotherapy session for 30-60 minutes. Subjects were asked to answer daily questionnaires assessing tolerability of the intervention. Mucositis was assessed at baseline, once weekly and at weeks 1/3/6 after CRT. The primary endpoint was patient tolerance, defined by the time the MCD was used and the patients' perception. Secondary outcomes were the degree (CTCAE v5.0) and duration of RIOM.
Results: Ten patients were eligible with a mean age of 62 years. Four patients received concurrent platinum-based CRT, whereas the others received radiotherapy alone. Overall, 214 CyT sessions were performed (73% of planned CyT sessions). The mean daily CyT duration was 48 minutes (range, 30-60 minutes). All patients reported cooling as comfortable. Nine completed the intervention, one terminated it early due to hypersalivation. No Grade 4 RIOM was observed. Grade 3 mucositis was observed in 4 and Grade 2 in 3 cases.
Conclusions: The Cooral System was well tolerated, with a duration of application that was acceptable for most patients. We concluded that the MCD can be safely used in patients undergoing CRT. A prospective phase II trial, assessing the efficacy in preventing RIOM, is planned.
期刊介绍：
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
